These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22578270)

  • 21. [Statins in chronic renal disease].
    Ferreira SR; Rocha AM; Saraiva JF
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG
    Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of older patients with dyslipidemia].
    González DF
    Semergen; 2014 May; 40 Suppl 1():17-21. PubMed ID: 25263639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
    Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
    Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
    Navaneethan SD; Perkovic V; Johnson DW; Nigwekar SU; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2009 Apr; (2):CD005019. PubMed ID: 19370615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating dyslipidemia: something more than giving statins.
    Masana L
    Clin Investig Arterioscler; 2019; 31(3):119-120. PubMed ID: 31014747
    [No Abstract]   [Full Text] [Related]  

  • 34. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
    Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based statin prescription for cardiovascular protection in renal impairment.
    Fabbian F; De Giorgi A; Pala M; Tiseo R; Manfredini R; Portaluppi F
    Clin Exp Nephrol; 2011 Aug; 15(4):456-63. PubMed ID: 21556807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of dyslipidemia in kidney transplantation.
    Ponticelli C; Arnaboldi L; Moroni G; Corsini A
    Expert Opin Drug Saf; 2020 Mar; 19(3):257-267. PubMed ID: 32073914
    [No Abstract]   [Full Text] [Related]  

  • 40. Statins and solid organ transplantation.
    Gazi IF; Liberopoulos EN; Athyros VG; Elisaf M; Mikhailidis DP
    Curr Pharm Des; 2006; 12(36):4771-83. PubMed ID: 17168777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.